Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SekirenB2 vs placebo for glucose absorption control during OGTT
jRCT1091220179Completed
- Sponsor
- Adaptgen Pharmaceutical
- Start
- May 2014
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sekiren B2 in type 2 diabetes mellitus (T2DM) and prediabetes (2 arms), sponsored by Adaptgen Pharmaceutical. Primary endpoint: Change in blood glucose level after ingestion. Started May 2014; status: completed.
02
Drugs
Sekiren B2
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on jRCT1091220179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220179.